Who
Rui Avelar
Officer
Company insider
Files Form 4 as: Officer, Evolus; Chief Medical Officer, Angiotech Pharmaceuticals.
In numbers
- Trades disclosed
- 51
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $2.1M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 8 Dec 2008
- Last trade
- 20 Mar 2026
- Last filed
- 20 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Mar 2026filed 20 Mar 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $15K3,119 at $4.75 | filing |
| 20 Mar 2026filed 20 Mar 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $15K3,119 at $4.75 | filing |
| 17 Mar 2026filed 18 Mar 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $147K29,996 at $4.89 | filing |
| 17 Mar 2026filed 18 Mar 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $147K29,996 at $4.89 | filing |
| 16 Mar 2026filed 18 Mar 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Code M | —8,804 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,804 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,804 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Code M | —8,804 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —94,913 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,913 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code A | —138,649 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,913 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code A | —138,649 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —94,913 at $0.00 | filing |
| 22 Dec 2025filed 29 Dec 2025 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $16K2,261 at $7.15 | filing |
| 12 May 2025filed 14 May 2025 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $33K3,385 at $9.87 | filing |
| 18 Mar 2025filed 20 Mar 2025 | EOLS EvolusBiotechnology | SEC FORM 4 Sold | $370K27,904 at $13.26 | filing |
| 7 Mar 2025filed 11 Mar 2025 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,776 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | EOLS Evolusoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,875 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | EOLS EvolusBiotechnology | SEC FORM 4 Code A | —23,776 at $0.00 | filing |
News
Lifecore Biomedical (NASDAQ:LFCR) vs. Evolus (NASDAQ:EOLS) Head to Head ComparisonEOLS · themarketsdaily.com · 14 Oct 2026Evolus (NASDAQ:EOLS) & Talphera (NASDAQ:TLPH) Financial ComparisonEOLS · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Rui Avelar; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.